Business Description
Medicenna Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA58490H1073
Description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 172.88 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.4 | |||||
| 3-Year EPS without NRI Growth Rate | 9.7 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -52.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 11.14 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.72 | |||||
| 9-Day RSI | 48.27 | |||||
| 14-Day RSI | 44.83 | |||||
| 6-1 Month Momentum % | -4.95 | |||||
| 12-1 Month Momentum % | 341.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.4 | |||||
| Quick Ratio | 11.4 | |||||
| Cash Ratio | 10.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.2 | |||||
| Shareholder Yield % | -14.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -147.92 | |||||
| ROA % | -94.55 | |||||
| ROIC % | -17081.01 | |||||
| ROC (Joel Greenblatt) % | -16527.03 | |||||
| ROCE % | -74.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.68 | |||||
| Price-to-Tangible-Book | 6.68 | |||||
| EV-to-EBIT | -5.72 | |||||
| EV-to-EBITDA | -5.73 | |||||
| EV-to-Forward-Revenue | 171.69 | |||||
| EV-to-FCF | -6.46 | |||||
| Price-to-Net-Current-Asset-Value | 6.68 | |||||
| Price-to-Net-Cash | 7.94 | |||||
| Earnings Yield (Greenblatt) % | -17.48 | |||||
| FCF Yield % | -12.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MDNAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medicenna Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.273 | ||
| Beta | 2.93 | ||
| Volatility % | 179.45 | ||
| 14-Day RSI | 44.83 | ||
| 14-Day ATR ($) | 0.118927 | ||
| 20-Day SMA ($) | 1.35559 | ||
| 12-1 Month Momentum % | 341.41 | ||
| 52-Week Range ($) | 0.2839 - 2.2 | ||
| Shares Outstanding (Mil) | 78.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medicenna Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medicenna Therapeutics Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medicenna Therapeutics Corp Frequently Asked Questions
What is Medicenna Therapeutics Corp(MDNAF)'s stock price today?
The current price of MDNAF is $1.27. The 52 week high of MDNAF is $2.20 and 52 week low is $0.28.
When is next earnings date of Medicenna Therapeutics Corp(MDNAF)?
The next earnings date of Medicenna Therapeutics Corp(MDNAF) is 2025-02-14 Est..
Does Medicenna Therapeutics Corp(MDNAF) pay dividends? If so, how much?
Medicenna Therapeutics Corp(MDNAF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers